Krithika. R. Iyengar, M. Komala, S. Satheeshkumar
Krithika. R. Iyengar*, Dr. M. Komala, Dr. S. Satheeshkumar
Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai – 600117, India.
Volume - 13,
Issue - 12,
Year - 2020
Colon-specific drug delivery systems (CDDS) are desirable for the treatment of a range of local diseases such as ulcerative colitis, Crohn’s disease, irritable bowel syndrome, chronic pancreatitis, and colonic cancer. Conventional treatment of these diseases is comprised of drug (chemotherapeutic agents) administration by parenteral route which leading to numerous undesirable effects. Drug targeting is delivery of drug to receptor, organ or to any other specific part of body exclusively. The targeted delivery to the colon can be a potential site for the systemic absorption of several drugs to treat non-colonic conditions and an increase in the availability of drugs at the targeted region and there by reducing the amount of drug required for same therapeutic effect, thus reducing the incidents of adverse effects. Drugs such as proteins and peptides that are known to degrade in the extreme gastric pH, if delivered to the colon intact, can be systemically absorbed by colonic mucosa. Several formulation approaches have been explored in the development colon-targeted drug delivery systems. These approaches involve the use of formulation components that interact with one or more aspects of gastrointestinal (GI) physiology, such as the difference in the pH along the GI tract, the presence of colonic microflora, and enzymes, to achieve colon targeting. New systems and technologies have also been developed for colon targeting and to overcome pervious method’s limitations. Colon targeting holds a great potential and still need more innovative work. This article highlights the factors influencing colon-specific drug delivery and colonic bioavailability and provides a systematic discussion of various conventional, as well as updated research on different approaches for formulation and evaluation currently being utilized for the development of CDDS.
Cite this article:
Krithika. R. Iyengar, M. Komala, S. Satheeshkumar. Colon Specific Drug Delivery Systems – Different Systems and Approaches: A Review. Research J. Pharm. and Tech. 2020; 13(12):6248-6258. doi: 10.5958/0974-360X.2020.01089.6
1. Krishnaiah Y S, Kumar B D, Satyanarayana S, Karthikeyan R S. Studies on the development of oral colon targeted drug delivery systems for celecoxib in the prevention of colorectal cancer. Journal of drug targeting. 2002; 10(3):247-254.
2. Encyclopedia of Pharmaceutical Technology Volume 2.
3. Mahkam M, Doosite L. The relation between swelling properties and cross linking of hydrogels designed for colon- specific drug delivery, Drug delivery, 12(6), 2005, 343-347.
4. Rao P R, Diwan P V. Formulation and in vitro evaluation of polymeric films, Drug Dev Indian Pharmac., 24, 1998, 327-36. Irit Gliko-Kabir, Boris Yagen, Abrahem Rubinstein et al. "Phosphated cross linked guar for colon-specific drug delivery I. Preparation and physicochemical characterization." Journal of Controlled Release 2000. 63: 121-127. Sarasija S and Hota A. Colon Specific Drug Delivery Systems, Ind J Pharm Sci., 2002; 62(1):1-8. Jain A, Gupta Y, Jain SK. "Potential of calcium pectinate beads for target specific drug release to colon." J Drug Target 2007. 15(4): 285-294.
5. Akala EO, Elekwachi O, Chase V, Johnson H, Marjorie L, Scott K. Organic Redox Initiated Polymerization Process for the Fabrication of Hydro Gel for Colon Specific Drug Delivery. Drug Dev Ind Pharm.,2003; 29:375-386.
6. Akhil Gupta, , Anuj Mittal, Alok Kumar Gupta – Colon Targeted Drug Delivery System – A review, Russian Journal of Biopharmaceuticals , June 2011 : 1-13
7. Dautry-Varsat A. Biochimie, 68, 1986, 375–81.
8. Krishnaiah Y S, Ramprasad Y V, Satyanarayana S, Seethadevi A, Nageswar Rao L Bhaskar P, Karthikeyan R R S. Guar gum as a carrier for colon specific delivery; Influence of metronidazole and tinidazole on in vitro release of albendazole from guar gum matrix tablets, Journal of pharmaceutical sciences, 4(3), 2001, 235-243.
9. Seth Amidon, Jack E. Brown, and Vivek S. Dave -Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches, Review Article - 2015; 16 (4); 731-741.
10. Chavan, MS, Sant, VP and Nagarsenker MS. Azo-containing Urethane Analogues for Colonic Drug Delivery: Synthesis, Characterization and In Vitro Evaluation. Journal of Pharmacy Pharmacology. 2001; 53: 895-900.
11. Orienti L, Trere R, Zecchi V. Hydrogels formed by cross linked polyvinyl alcohol as colon specific drug delivery systems, Drug development and Industrial Pharmacy 27(8 2001, 877-884Mundargi RC, Patil SA, Agnihotri SA et al. "Development of polysaccharide-based colon targeted drug delivery systems for the treatment of ameobiasis." Drug Dev Ind Pharm 2007. 33(3): 255- 264.
12. Multiparticulate Formulation Approach to Colon Specific Drug Delivery: Current Perspectives J Pharm Pharmaceut Sci (www. cspsCanada.org), 2006; 9 (3): 327-338.
13. Krishnaiah Y S, Kumar B D, Satyanarayana S, Karthikeyan R S. Studies on the development of oral colon targeted drug delivery systems for celecoxib in the prevention of colorectal cancer. Journal of drug targeting. 2002; 10(3):247-254.
14. Advances in controlled drug delivery system- N.K. Jain.
15. Philip Anil, Betty Philip. Colon Drug Delivery System: A Review on Primary and Novel Approch. Oman Medical Journal, 2010; 25(2).
16. Tarak Jayraj Mehta, Mr A.D. Patel, Dr Mukesh R. Patel, Dr N. M. Patel – Need of Colon Specific Drug Delivery System: Review on Primary and Novel Approaches , International Journal of Pharma Research and Development, 2014 ; 3 (1) ; 134-148. McConnell E L. "An in vivo comparison of intestinal pH and bacteria as physiological trigger mechanisms for colonic targeting in man," J Control Release 2008; 130:154-160.
17. Bronsted H, Hovgaard L, Simonsen L. Dextran hydrogels for colon-specific drug delivery, Part 3. In vitro and in vivo degradation, STP-Pharm-Sciences, 5(1), 1995, 60-64.NorihitoShimono, Toshihito Takatori, Masumi Veda et al. "Chitosan dispersed system for the colon-specific drug delivery." International Journal of Pharmaceutics 2002. 245: 45-54.
18. Asha Patel, Nilam Bhatt, Dr. K. R. Patel, Dr. N. M. Patel, Dr. M. R. Patel, Journal of Pharmaceutical Science and Bioscientific Research (JPSBR) ; 2011 ; 1 (1); 37-49. Yang L. "Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation." Int J Pharm 2002; 235: 1.15.
19. Malayandi R, Kondamudi P, Ruby PK, Aggarwal D. Biopharmaceuticalconsiderationsandcharacterizationsindevelopment of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv Transl Res. 2014;4(2):187–202.
20. Sinha V R, Kumria R. Microbially triggered drug delivery to the colon, European journal of pharmaceutical sciences, 18(1), 2003, 3-18. Novel Colon Specific Drug Delivery System : A Review, Madhu E. Nicholas, International Journal of Pharmaceutical Science and Research ; 2011 ; 7 ; 2545-2561
21. Samyn C, Kalala. W, Vanden Mooter et al (1995). "Synthesis and in vitro biodegradation of poly (ether-ester) azo polymers designed for colon targeting." International Journal of Pharmaceutics. 121: 211-216.
22. Modified-Release Solid Formulations for Colon Delivery Recent Patents on Drug Delivery and Formulation 2007, 1: 53-63.
23. Vyas, S.P., Khar, R.K., In: "Controlled drug delivery, Concepts and Advances ", 1s t edition, Vallavbhprakashan: (2002), 219-224, 258-268.
24. Higuchi T, Stella V(ed.). Prodrugs: an overview and definition. Inc: Prodrugs as Novel Drug Delivery Systems, ACS Symposium Series, Washington, DC: American Chemical Society, 1975, 1-115.
25. Ramprasad Y V, Krishnaiah Y S, Satyanarayana S. Studies of guar gum compression-coated 5-aminosalicylic acid tablets for colon-specific drug delivery, Drug development and industrial pharmacy, 25(5), 1999, 651-657.
26. S.P. Vyas and R.K. Khar – Targeted and Controlled Drug Deliver – Novel Carrier System